James Franck Professor
Depts of Chemistry and Radiation & Cellular Oncology
University of Chicago
Chairman of the Board
RiMO Therapeutics and Coordination Pharmaceuticals
RiMO Therapeutics, Inc. (RiMO), is a privately held, clinical stage oncology drug development company that aims to address unmet medical needs and improve patient care. Our proprietary Radio-immuno Metal-Organic (RiMO) technology platform greatly enhances the efficacy of X-ray radiotherapy via the unprecedented radiotherapy-radiodynamic therapy (RT-RDT) mode of action. RiMO clinical candidates are intrinsically non-toxic and greatly reduce X-ray doses needed to eradicate local tumors in mouse models. The RiMO technology also allows to combine multiple therapeutic modalities to increase efficacy while simultaneously reducing toxicity. RiMO products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.
Coordination Pharmaceuticals, Inc. (CPI) is a privately held oncology drug development company that aims to address unmet medical needs and improve patient care. Its key technology, licensed from the University of Chicago and developed in the research group Prof. Wenbin Lin, is based on nanoscale coordination polymers (NCPs) which are constructed from metal-connecting points and organic bridging ligands via self-assembly processes. NCPs can combine the advantages of both organic and inorganic nanoparticles to afford an entirely new family of nanotherapeutics that overcome many drawbacks of existing drug delivery systems by virtue of tunable compositions, sizes and shapes, high drug loadings, ease of surface modiﬁcation, and intrinsic biodegradability. NCPs allow for the co-delivery of synergistic chemotherapeutics and/or biologics with disparate physical and chemical properties; such chemotherapeutic and or biologic combinations cannot be delivered with existing nanotechnologies. The NCP technology enhances therapeutic efficacy while reducing general toxicity and overcoming drug resistance in several cancer models.